Increased risk of malignancies in a population-based study of 818 soft-tissue sarcoma patients

ABSTRACT Soft-tissue sarcomas (STS) have been associated with various rare cancer syndromes and occur at increased frequencies in survivors of childhood cancer. Also adult patients with STS

have been suggested to be at an increased risk of additional malignancies. After exclusion of syndrome-associated and radiation-induced sarcomas, we studied multiple primary malignancies in

a population-based cohort of 818 patients with primary STS of the extremities and the trunk wall. In total, 203 other malignancies developed in 164 (20%) patients median 10 (0–32) years

before and median 4 (0–35) years after the sarcoma diagnosis. Standardised morbidity ratios (SMRs) were determined for primary malignancies following a STS. Hereby individuals who had

developed a STS were identified to be at increased risk of second primary malignancies (SMR for all malignant tumours=1.3; 95% CI=1.0–1.5; _P_=0.02) with STS being the only specific tumour

type that occurred at an increased risk (SMR=17.6; 95% CI=8.1–33.5; _P_<0.001). Hence, this population-based series demonstrates a high frequency of second primary tumours among STS

patients and indicates a particularly increased risk of developing a new STS. SIMILAR CONTENT BEING VIEWED BY OTHERS DESCRIPTIVE ANALYSIS OF INCIDENCE, DEMOGRAPHIC CHARACTERISTICS, AND

SURVIVAL OUTCOMES OF SOFT-TISSUE SARCOMA OF THE EXTREMITIES IN SAUDI ARABIA Article Open access 25 November 2024 UK GUIDELINES FOR THE MANAGEMENT OF SOFT TISSUE SARCOMAS Article Open access

11 May 2024 A DEMOGRAPHIC AND CLINICAL PANORAMA OF A SIXTEEN-YEAR COHORT OF SOFT TISSUE SARCOMA PATIENTS IN BRAZIL Article Open access 18 November 2021 MAIN Soft-tissue sarcomas (STS)

represent less than 1% of all malignancies and constitute a group of biologically heterogeneous tumours. Some subtypes, for example, synovial sarcoma and myxoid liposarcoma are characterised

by specific gene fusions, whereas others, for example, pleomorphic liposarcoma, leiomyosarcoma, and undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma (MFH) carry multiple

complex genetic alterations (Helman and Meltzer, 2003). An increased risk of STS has been found in survivors of various types of childhood cancers, including retinoblastoma, leukaemia,

Wilms' tumour, and Hodgkin's lymphoma (Breslow et al, 1995; Beaty et al, 1995; Moll et al, 1997; Neglia et al, 2001; Bisogno et al, 2004; Fletcher et al, 2004; Kleinerman et al,

2005). Also survivors of childhood STS, osteosarcoma, and Ewing sarcoma have been shown to be at increased risk of multiple primary malignancies, including bone sarcomas and STS (Heyn et al,

1993; Pratt et al, 1997; Neglia et al, 2001; Paulussen et al, 2001; Bacci et al, 2005; Cohen et al, 2005; Bassal et al, 2006). Development of multiple primary malignancies may also

represent a side effect of chemotherapy or radiotherapy, which yield an increased risk of secondary malignancies, including STS (Brady et al, 1992; Kony et al, 1997; Neglia et al, 2001;

Sheppard and Libshitz, 2001; Cormier and Pollock, 2004; Kirova et al, 2005; Thijssens et al, 2005; Virtanen et al, 2006). Children with STS who have been treated with radiotherapy have a

nearly eight-fold risk of developing a second malignant neoplasm, including bone and STS (Cohen et al, 2005). Based on current knowledge heredity, probably accounts for only a small subset

of STS, although these tumours have been associated with several hereditary syndromes (Lynch et al, 2003). Among these, the most well-known are neurofibromatosis due to mutations in the

_NF1_ gene with an increased risk for neurofibrosarcomas and the Li–Fraumeni syndrome caused by germline mutations in _TP53_ with increased risks for STS, leukaemia, brain tumours, and

breast cancer (Lynch et al, 2003). However, STS have been associated also with premature ageing within the Werner syndrome and Rothmund–Thomson syndrome due to mutations in the genes _WRN_

and _RECQ4_ (Yu et al, 1996; Lindor et al, 2000) and has been described to develop in melanoma syndrome kindreds with _CDKN2A_ mutations and in Lynch syndrome families with mutations in

mismatch-repair genes (Sijmons et al, 2000; Lynch et al, 2002, 2003; Medina Arana et al, 2002; Hirata et al, 2006). In addition, STS occur in familial forms with yet unidentified modes of

inheritance and underlying genetic causes. Two recent studies have described development of multiple primary malignancies in adult STS patients, and also suggested that STS patients may be

at risk of developing a second primary STS (Merimsky et al, 2001; Tateishi et al, 2005). We used the southern part of the Swedish Cancer Registry to identify all individuals with STS during

the time period 1964–2001 to characterise development of multiple primary malignancies in this cohort and to assess the risk of a second primary malignancy after STS. MATERIALS AND METHODS

THE STS COHORT The National Swedish Cancer Registry is based on the International Classification of Diseases (ICD) codes and is, because of mandatory cancer registration by both pathologists

and clinicians, population-based and estimated to contain 99% of all malignant diagnoses. The study is based on the southern Sweden (currently 1.7 million inhabitants) part of the registry.

All individuals diagnosed with primary STS of the extremities and trunk wall during 1964–2001 were identified. Medical records were in all patients scrutinised for pertinent data, that is,

syndrome-associated diseases, and previous treatment with radiotherapy and/or chemotherapy, and all tumours have repeatedly been reviewed by sarcoma pathologists at our tumour centre, and

the vast majority of these tumours had been reviewed by the Scandinavian Sarcoma Review Board (Rydholm, 1983; Gustafson, 1994; Engellau, 2004). We excluded children (<16 years of age at

diagnosis), sarcomas associated with neurofibromatosis type I, dermal sarcomas, and STS that developed in previously irradiated fields or were associated with Stewart–Treves syndrome.

Hereafter, 824 patients with primary STS of the extremities or the trunk wall remained, but six patients who died at the time of STS diagnosis were excluded, and the study was thus based on

818 individuals (Table 1). The histopathological reports were reviewed to confirm primary tumour origin, location, and subtype. DEVELOPMENT OF OTHER PRIMARY MALIGNANCIES All other

malignancies that had developed in these 818 patients during 1958–2004 were identified in the Cancer Registry. The histopathological reports regarding the other malignancies were collected

from 169 cases, whereas data in 34 cases relied on information from the Cancer Registry only, most often because of missing data at the local pathology departments. All previous radiotherapy

fields were re-evaluated regarding overlap with the site of the secondary tumour, but only one tumour – a squamous cell carcinoma that developed 26 years after irradiation for a liposarcoma

of the groin – was excluded since it was regarded as radiation-induced. Soft-tissue sarcoma that developed at another anatomical site before the development of any metastases (in the lungs

or at other sites such as lymph nodes or skeletal metastases) were regarded as multiple primary STS, whereas STS that developed at the same location as the primary tumour or in patients with

known metastases were regarded as local recurrences and were thus not included in the analysis (Antonescu et al, 2000). Furthermore, among the patients with second primary STS, five of

seven remained free of metastases after long-term follow-up. RISK ASSESSMENT The patients within the cohort were followed from the time of STS diagnosis to death (when they were censored) or

until 31st December 2004 when the study was closed. The cancer incidence within the southern Swedish part of the Cancer Registry was used as a reference. The analysis was stratified by sex,

calendar year, and 5-year age groups, that is, the cancer incidence in the STS cohort was compared to the cancer incidence in the reference population. The risk estimates were based only on

tumours that developed after the STS because of difficulties in compensating for death rates from prior malignancies and after exclusion of a squamous cell carcinoma of the skin that

developed within a previously irradiated field. Standardised morbidity ratios (SMRs) were calculated by dividing the observed number of cancer cases by the expected number for the total

cohort (818 patients) and also for subgroups with respect to sex, age at STS diagnosis, and with exclusion of the 77 individuals with another primary malignancy before the STS diagnosis.

Ethical permission for the study was granted from the Lund University ethics committee. RESULTS PRIMARY TUMOURS PRECEDING OR FOLLOWING THE STS Among the 818 patients, 164 (20%) developed 203

additional primary malignancies preceding or following the STS (Table 1). The median age at the STS diagnosis was 66 (range 16–98) years and the median age at the first malignant diagnosis

among patients with multiple tumours, irrespective of tumour type, was 69 (31–91) years. The other malignancies developed median 10 (0–32) years before and median 4 (0–35) years after the

sarcoma diagnosis. One additional malignancy was found in 131 individuals, two additional malignancies in 27, and three additional malignancies developed in six patients. In relation to the

type of STS, multiple primary malignancies occurred in 93 of 306 (30%) patients with MFH, in 31 of 143 (22%) patients with leiomyosarcomas, 19 of 81 (23%) with liposarcomas, six of 58 (10%)

with synovial sarcomas, 19 of 35 (54%) with malignant peripheral nerve sheath tumours (MPNST), and in 35 of 161 (22%) patients with STS of other subtypes. Primary malignancies (_n_=90) that

developed prior to the STS diagnosis were identified in 77 patients, nine of whom had developed two and two of whom had developed three primary malignancies. The most common cancer types

were breast cancer (_n_=19), prostate cancer (_n_=10), and malignant melanoma (_n_=10) (Table 2). Second primary malignancies (_n_=113) after the STS were identified in 96 patients. Of

these, 82 patients developed one additional malignancy, 11 developed two, and three patients developed three additional malignancies. The second primary malignancies developed at median age

76 (45–95) years (Table 1). The most frequent tumour types after the STS diagnosis were prostate cancer (_n_=18) and colorectal cancer (_n_=16) (Table 2). A second STS at another anatomical

location developed in seven patients mean 4 (range 2–5) years after the primary diagnosis, and two of these patients developed a third subsequent STS (Table 3). Of these nine tumours, three

were of another histopathologic subtype than the primary tumour. These patients did not have metastases at other sites and only two of seven individuals developed subsequent lung metastases

after 47 and 50 moths, respectively (Table 3). Among the 96 patients who developed other malignancies following the STS, radiotherapy had been administered preoperatively to one patient and

postoperatively to 22 patients, and chemotherapy had been given preoperatively to one patient and postoperatively to three patients. SMR CALCULATIONS The follow-up for the whole cohort

encompassed 6910 person years and during this time 113 malignancies developed compared to the expected number of 90, which corresponds to a SMR for all malignancies of 1.3 (95% CI=1.0–1.5;

_P_=0.02) (Table 2). The only specific tumour type that developed at increased risk was STS with a SMR of 17.6 (95% CI=8.1–33.5; _P_<0.001) (Table 2). When the 77 individuals with another

malignancy before the STS were excluded, similar results were obtained with a significantly increased risk of all malignancies (SMR, all tumours=1.3; 95% CI=1.0–1.5; _P_=0.03) and a

specifically increased risk of STS (SMR=17.1; 95% CI=7.4–33.7). The increased risk of second primary tumours was particularly high in individuals who developed a STS after age 64 (SMR, all

tumours=1.4; 95% CI=1.2–1.8; _P_<0.01) and an increased risk of lung cancer was identified in this subgroup (SMR=2.2; 95% CI=0.9–4.5; _P_=0.04). DISCUSSION Several causes, including

treatment-related factors and heredity, are likely to underlie development of multiple primary malignancies (Kony et al, 1997). Based on data from the National Swedish Cancer Registry, two

or more primary malignancies develop in 8–10% of all cancer patients, whereas three or more malignancies are found in less than 1% of the patients (Swedish board of health and welfare;

http://www.sos.se/sosmenye.htm). Centre-based studies have suggested that 7–10% of adult STS patients develop multiple primary malignancies (before or after the sarcoma diagnosis) (Hartley

et al, 1993; Merimsky et al, 2001; Tateishi et al, 2005). Development of a third primary tumour has in the previous studies been reported in 1.6–2% of the patients (Merimsky et al, 2001;

Tateishi et al, 2005). In this study, one second primary malignancy developed in 16% of the patients and two or more other malignancies were diagnosed in 4% of the patients, hence at higher

rates than among cancer patients in general as well as in previous reports on adult STS patients. Since we excluded individuals with hereditary syndromes and STS within irradiated fields,

and since chemotherapy had only been administered to four patients, genetic and treatment-related factors are not likely to explain the occurrence of multiple primary tumours in our series.

The frequency of multiple primary malignancies varied between the different STS subtypes, but may be influenced by survival differences for the different histopathological subtypes. The

lowest rate of second malignancies was observed in patients with synovial sarcomas (only six of 58 developed another malignancy), which is in line with the results from Tateishi et al

(2005), who did not observe any second malignancies in individuals with synovial sarcoma. Two previous studies have suggested that the risk of development of multiple primary malignancies is

particularly high among STS patients with MFHs, including myxofibrosarcoma (Merimsky et al, 2001; Tateishi et al, 2005). In our series, multiple primary tumours most frequently occurred in

patients diagnosed with MPNST (19 of 35) followed by MFH (93 of 306) (Table 1). Since patients with neurofibromatosis type I were excluded from the study, the high frequency of multiple

primary malignancies in patients with MPNST is not likely to be explained by this syndrome. Patients with neurofibromatosis type I are at a higher risk of several tumour types, including

MPNST, chronic myelogenous leukaemia and gliomas (Listernick et al, 1999; Korf, 2000). However, none of these tumour types were observed among patients diagnosed with MPNST, in whom the most

common second tumour types were breast cancer followed by prostate cancer, STS, and tumours of the urinary tract. Merimsky et al (2001) identified renal cell cancer and STS as the most

common second tumour types in their study of a mixed STS cohort, and although we confirm an increased frequency of STS, we did not find any increased risk of renal cell cancer. Tateishi et

al (2005) showed that the risk of multiple malignancies increased with the age at diagnosis. This finding seems to be in accordance with our study, since patients diagnosed with a STS after

age 64 indicated a larger increase compared to individuals below 65 years of age. We analyzed the risk of multiple primary tumours in patients previously diagnosed with STS. Overall, 113

second primary malignancies following the sarcoma developed in 96 (12%) patients. An increased SMR (1.3) for all malignant tumours was found, with the only specific tumour type to develop at

an increased SMR (17.6) being a second STS. Among the seven patients who developed a second STS, three of nine tumours were of another histopathologic subtype and two individuals developed

three STS (Table 3). Although we required that the second STS should be at another anatomical location and should develop before any lung metastases, it is difficult to determine whether

multiple STS in the same individual represent multiple primary tumours or rather an unusual pattern of metastatic disease. Indeed, occasional cases with soft-tissue metastases from

liposarcomas, sometimes several years after the primary tumour, have been reported (Antonescu et al, 2000), but only one of the patients in our series presented with multiple liposarcomas.

The observation of STS at different anatomical sites and with different histopathology is in line with reports on multiple primary STS in a small subset (0.2%) of STS patients (Antonescu et

al, 2000; Grobmyer et al, 2004). Because of the rarity of STS, specific associations with other cancer types may be difficult to recognise. In the context of familial sarcoma, an association

with several tumour types has been described and besides the well-known syndromes such as neurofibromatosis and Li–Fraumeni syndrome, STS have been observed as a rare tumour manifestation

in various other hereditary syndromes together with, for example, melanoma, pancreatic cancer, and colorectal cancer (Lynch et al, 2003). Although no specific tumour type other than STS

occurred at significantly increased risk in the present study, malignant melanoma developed in 12 patients and pancreatic cancer in four. Development of STS has been described in association

with the _CDKN2A_ mutation associated with the familial atypical multiple-mole melanoma syndrome (Lynch et al, 2002, 2003). Also, endometrial cancer occurred in 11 women and colorectal

cancer in 21 individuals, and some of these cases could signify Lynch syndrome, since STS has been described herein (Sijmons et al, 2000; Medina Arana et al, 2002; Hirata et al, 2006). Data

on family history of cancer are not available in this material, but because of the links of STS described to various cancer syndromes, we suggest that a family history of cancer should be

obtained in STS patients. Specific attention should perhaps be given to cases of melanoma, endometrial cancer, and colorectal cancer in the individual or in the family, since these tumour

types may be prevented through screening programmes, whereas the occurrence of multiple primary STS needs further characterisation in order to clarify its causes. CHANGE HISTORY * _ 16

NOVEMBER 2011 This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication _ REFERENCES * Antonescu CR, Elahi A, Healey

JH, Brennan MF, Lui MY, Lewis J, Jhanwar SC, Woodruff JM, Ladanyi M (2000) Monoclonality of multifocal myxoid liposarcoma: confirmation by analysis of TLS-CHOP or EWS-CHOP rearrangements.

_Clin Cancer Res_ 6: 2788–2793 CAS  PubMed  Google Scholar  * Bacci G, Longhi A, Barbieri E, Ferrari S, Mercuri M, Briccoli A, Versari M, Pignotti E, Picci P (2005) Second malignancy in 597

patients with Ewing sarcoma of bone treated at a single institution with adjuvant and neoadjuvant chemotherapy between 1972 and 1999. _J Pediatr Hematol Oncol_ 27: 517–520 Article  Google

Scholar  * Bassal M, Mertens AC, Taylor L, Neglia JP, Greffe BS, Hammond S, Ronckers CM, Friedman DL, Stovall M, Yasui YY, Robison LL, Meadows AT, Kadan-Lottick NS (2006) Risk of selected

subsequent carcinomas in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. _J Clin Oncol_ 24: 476–483 Article  Google Scholar  * Beaty III O, Hudson MM,

Greenwald C, Luo X, Fang L, Wilimas JA, Thompson EI, Kun LE, Pratt CB (1995) Subsequent malignancies in children and adolescents after treatment for Hodgkin's disease. _J Clin Oncol_

13: 603–609 Article  Google Scholar  * Bisogno G, Sotti G, Nowicki Y, Ferrari A, Garaventa A, Zanetti I, Favre C, Schiavetti A, Tamaro P, Carli M (2004) Soft tissue sarcoma as a second

malignant neoplasm in the pediatric age group. _Cancer_ 100: 1758–1765 Article  Google Scholar  * Brady MS, Gaynor JJ, Brennan MF (1992) Radiation-associated sarcoma of bone and soft tissue.

_Arch Surg_ 127: 1379–1385 Article  CAS  Google Scholar  * Breslow NE, Takashima JR, Whitton JA, Moksness J, D'Angio GJ, Green DM (1995) Second malignant neoplasms following treatment

for Wilm's tumor: a report from the National Wilms' Tumor Study Group. _J Clin Oncol_ 13: 1851–1859 Article  CAS  Google Scholar  * Cohen RJ, Curtis RE, Inskip PD, Fraumeni Jr JF

(2005) The risk of developing second cancers among survivors of childhood soft tissue sarcoma. _Cancer_ 103: 2391–2396 Article  Google Scholar  * Cormier JN, Pollock RE (2004) Soft tissue

sarcomas. _CA Cancer J Clin_ 54: 94–109 Article  Google Scholar  * Engellau J (2004) Prognostic factors in soft tissue sarcoma. _Orthop Scand Suppl_ 314: 15–23 Google Scholar  * Fletcher O,

Easton D, Anderson K, Gilham C, Jay M, Peto J (2004) Lifetime risks of common cancers among retinoblastoma survivors. _J Natl Cancer Inst_ 96: 357–363 Article  Google Scholar  * Grobmyer SR,

Luther N, Antonescu CR, Singer S, Brennan MF (2004) Multiple primary soft tissue sarcomas. _Cancer_ 101: 2633–2635 Article  Google Scholar  * Gustafson P (1994) Soft tissue sarcoma:

epidemiology and prognosis in 508 patients. _Acta Orthop Scand Suppl_ 259: 1–31 CAS  PubMed  Google Scholar  * Hartley AL, Blair V, Harris M, Birch JM, Banerjee SS, Freemont AJ, McClure J,

McWilliam LJ (1993) Multiple primary tumours in a population-based series of patients with histopathologically peer-reviewed sarcomas. _Br J Cancer_ 68: 1243–1246 Article  CAS  Google

Scholar  * Helman LJ, Meltzer P (2003) Mechanisms of sarcoma development. _Nat Rev Cancer_ 3: 685–694 Article  CAS  Google Scholar  * Heyn R, Haeberlen V, Newton WA, Ragab AH, Raney RB,

Tefft M, Wharam M, Ensign LG, Maurer HM (1993) Second malignant neoplasms in children treated for rhabdomyosarcoma. Intergroup Rhabdomyosarcoma Study Committee. _J Clin Oncol_ 11: 262–270

Article  CAS  Google Scholar  * Hirata K, Kanemitsu S, Nakayama Y, Nagata N, Itoh H, Ohnishi H, Ishikawa H, Furukawa Y (2006) A novel germline mutation of MSH2 in a hereditary nonpolyposis

colorectal cancer patient with liposarcoma. _Am J Gastroenterol_ 101: 193–196 Article  CAS  Google Scholar  * Kirova YM, Vilcoq JR, Asselain B, Sastre-Garau X, Fourquet A (2005)

Radiation-induced sarcomas after radiotherapy for breast carcinoma: a large-scale single-institution review. _Cancer_ 104: 856–863 Article  Google Scholar  * Kleinerman RA, Tucker MA, Tarone

RE, Abramson DH, Seddon JM, Stovall M, Li FP, Fraumeni Jr JF (2005) Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up. _J Clin Oncol_

23: 2272–2279 Article  Google Scholar  * Kony SJ, de Vathaire F, Chompret A, Shamsaldim A, Grimaud E, Raquin MA, Oberlin O, Brugieres L, Feunteun J, Eschwege F, Chavaudra J, Lemerle J,

Bonaiti-Pellie C (1997) Radiation and genetic factors in the risk of second malignant neoplasms after a first cancer in childhood. _Lancet_ 350: 91–95 Article  CAS  Google Scholar  * Korf BR

(2000) Malignancy in neurofibromatosis type 1. _Oncologist_ 5: 477–485 Article  CAS  Google Scholar  * Lindor NM, Furuichi Y, Kitao S, Shimamoto A, Arndt C, Jalal S (2000) Rothmund–Thomson

syndrome due to RECQ4 helicase mutations: report and clinical and molecular comparisons with Bloom syndrome and Werner syndrome. _Am J Med Genet_ 90: 223–228 Article  CAS  Google Scholar  *

Listernick R, Charrow J, Gutmann DH (1999) Intracranial gliomas in neurofibromatosis type 1. _Am J Med Genet_ 89: 38–44 Article  CAS  Google Scholar  * Lynch HT, Brand RE, Hogg D, Deters CA,

Fusaro RM, Lynch JF, Liu L, Knezetic J, Lassam NJ, Goggins M, Kern S (2002) Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole

melanoma-pancreatic carcinoma-prone families: the familial atypical mole melanoma-pancreatic carcinoma syndrome. _Cancer_ 94: 84–96 Article  CAS  Google Scholar  * Lynch HT, Deters CA, Hogg

D, Lynch JF, Kinarsky Y, Gatalica Z (2003) Familial sarcoma: challenging pedigrees. _Cancer_ 98: 1947–1957 Article  Google Scholar  * Medina Arana V, Barrios del Pino Y, Garcia-Castro C,

Gonzalez-Aguilera JJ, Fernandez-Peralta A, Gonzalez Hermoso F (2002) Highly aggressive leiomyosarcoma associated with Lynch II syndrome: increasing the range of extracolonic cancers related

with hereditary non-polyposis colonic cancer. _Ann Oncol_ 13: 807–808 Article  CAS  Google Scholar  * Merimsky O, Kollender Y, Issakov J, Bickels J, Flusser G, Gutman M, Lev-Chelouche D,

Inbar M, Meller I (2001) Multiple primary malignancies in association with soft tissue sarcomas. _Cancer_ 91: 1363–1371 Article  CAS  Google Scholar  * Moll AC, Imhof SM, Bouter LM, Tan KE

(1997) Second primary tumors in patients with retinoblastoma. A review of the literature. _Ophthalmic Genet_ 18: 27–34 Article  CAS  Google Scholar  * Neglia JP, Friedman DL, Yasui Y,

Mertens AC, Hammond S, Stovall M, Donaldson SS, Meadows AT, Robison LL (2001) Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study. _J Natl

Cancer Inst_ 93: 618–629 Article  CAS  Google Scholar  * Paulussen M, Ahrens S, Lehnert M, Taeger D, Hense HW, Wagner A, Dunst J, Harms D, Reiter A, Henze G, Niemeyer C, Gobel U, Kremens B,

Folsch UR, Aulitzky WE, Voute PA, Zoubek A, Jurgens H (2001) Second malignancies after Ewing tumor treatment in 690 patients from a cooperative German/Austrian/Dutch study. _Ann Oncol_ 12:

1619–1630 Article  CAS  Google Scholar  * Pratt CB, Meyer WH, Luo X, Cain AM, Kaste SC, Pappo AS, Rao BN, Fleming ID, Jenkins III JJ (1997) Second malignant neoplasms occurring in survivors

of osteosarcoma. _Cancer_ 80: 960–965 Article  CAS  Google Scholar  * Rydholm A (1983) Management of patients with soft-tissue tumors. Strategy developed at a regional oncology center. _Acta

Orthop Scand Suppl_ 203: 13–77 CAS  PubMed  Google Scholar  * Sheppard DG, Libshitz HI (2001) Post-radiation sarcomas: a review of the clinical and imaging features in 63 cases. _Clin

Radiol_ 56: 22–29 Article  CAS  Google Scholar  * Sijmons R, Hofstra R, Hollema H, Mensink R, van der Hout A, Hoekstra H, Kleibeuker J, Molenaar W, Wijnen J, Fodde R, Vasen H, Buys C (2000)

Inclusion of malignant fibrous histiocytoma in the tumour spectrum associated with hereditary non-polyposis colorectal cancer. _Genes Chromosomes Cancer_ 29: 353–355 Article  CAS  Google

Scholar  * Tateishi U, Hasegawa T, Yamamoto S, Yamaguchi U, Yokoyama R, Kawamoto H, Satake M, Arai Y (2005) Incidence of multiple primary malignancies in a cohort of adult patients with soft

tissue sarcoma. _Jpn J Clin Oncol_ 35: 444–452 Article  Google Scholar  * Thijssens KM, van Ginkel RJ, Suurmeijer AJ, Pras E, van der Graaf WT, Hollander M, Hoekstra HJ (2005)

Radiation-induced sarcoma: a challenge for the surgeon. _Ann Surg Oncol_ 12: 237–245 Article  Google Scholar  * Virtanen A, Pukkala E, Auvinen A (2006) Incidence of bone and soft tissue

sarcoma after radiotherapy: a cohort study of 295,712 Finnish cancer patients. _Int J Cancer_ 118: 1017–1021 Article  CAS  Google Scholar  * Yu CE, Oshima J, Fu YH, Wijsman EM, Hisama F,

Alisch R, Matthews S, Nakura J, Miki T, Ouais S, Martin GM, Mulligan J, Schellenberg GD (1996) Positional cloning of the Werner's syndrome gene. _Science_ 272: 258–262 Article  CAS 

Google Scholar  Download references ACKNOWLEDGEMENTS Financial support was granted from the Swedish Cancer Society, the Swedish Childrens' Cancer Fund, the Swedish Research Council, the

Nilsson Cancer Fund, and the Research Funds at the Lund University Hospital. AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Department of Oncology, Institute of Clinical Sciences, Lund

University Hospital, Lund, Sweden J Fernebro, H Olsson, J Engellau & M Nilbert * Department of Cancer Epidemiology, Institute of Clinical Sciences, Lund University Hospital, Lund, SE-221

85, Sweden A Bladström & H Olsson * Department of Orthopedics, Institute of Clinical Sciences, Lund University Hospital, Lund, SE-221 85, Sweden A Rydholm & P Gustafson Authors * J

Fernebro View author publications You can also search for this author inPubMed Google Scholar * A Bladström View author publications You can also search for this author inPubMed Google

Scholar * A Rydholm View author publications You can also search for this author inPubMed Google Scholar * P Gustafson View author publications You can also search for this author inPubMed 

Google Scholar * H Olsson View author publications You can also search for this author inPubMed Google Scholar * J Engellau View author publications You can also search for this author

inPubMed Google Scholar * M Nilbert View author publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to J Fernebro. RIGHTS AND

PERMISSIONS From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of

this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Fernebro, J., Bladström, A., Rydholm, A. _et al._

Increased risk of malignancies in a population-based study of 818 soft-tissue sarcoma patients. _Br J Cancer_ 95, 986–990 (2006). https://doi.org/10.1038/sj.bjc.6603401 Download citation *

Received: 24 April 2006 * Revised: 04 September 2006 * Accepted: 04 September 2006 * Published: 26 September 2006 * Issue Date: 23 October 2006 * DOI: https://doi.org/10.1038/sj.bjc.6603401

SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to

clipboard Provided by the Springer Nature SharedIt content-sharing initiative KEYWORDS * epidemiology * soft-tissue sarcoma * multiple primary malignancies * population-based * cancer risk